GLP-1 Telehealth and Compounding Arrangements: Structuring for Compliance

Telehealth platforms marketing GLP-1 and compounded weight-loss prescriptions increasingly route a single patient through three separate businesses: a telehealth platform that handles marketing and technology, a physician practice that writes the prescription, and a compounding pharmacy that fills it. The fee arrangements binding those three parties together, and how much control the platform exercises over the prescriber, now sit at the center of active federal and state enforcement. The Anti-Kickback Statute exposes pharmacies and platforms that tie fees to prescription volume, and state corporate practice of medicine doctrines expose platforms that direct clinical decisions the prescriber is supposed to control alone.

The Prescriber-Pharmacy-Platform Structure

A typical GLP-1 telehealth arrangement separates the entity that owns the technology and marketing operation, often structured as a management services organization (MSO), from the entity that employs or contracts with the prescriber, usually a physician-owned professional corporation (PC). The compounding pharmacy sits alongside both, filling the prescriptions the PC's prescribers write after an online intake. Structured correctly, the MSO owns the platform, the marketing, and the non-clinical administrative work, while the PC retains full authority over prescribing decisions. A compounding pharmacy's own regulatory obligations run independently of how the platform and prescriber are organized, a distinction covered in 503A vs 503B: Which Framework Governs Your Compounding, but the fee arrangement connecting all three parties is where enforcement risk concentrates.

Fee Arrangements and Anti-Kickback Statute Exposure

The federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), makes it a felony to knowingly and willfully offer, pay, solicit, or receive remuneration to induce referrals or business for which payment may be made under a federal health care program. A platform fee that rises with the number of prescriptions written, or a per-fill fee paid to a pharmacy, is the arrangement the statute targets directly. The HHS Office of Inspector General (OIG) addressed this in its July 20, 2022 Special Fraud Alert on telemedicine, telehealth, and telemarketing arrangements, warning practitioners that compensation tied to the volume of federal health care program business generated is a hallmark of the fraud schemes OIG had investigated. The safer path runs through the personal services and management contracts safe harbor, 42 CFR § 1001.952(d), which requires a fee methodology fixed in advance, consistent with fair market value, and never adjusted for referral volume. OIG's June 2025 Advisory Opinion 25-03 approved exactly that kind of structure, an hourly clinician lease fee plus a separately stated administrative fee, paired with an arrangement that left prescribing authority entirely with the physician-owned practice.

A platform fee that moves with the volume of prescriptions written is the exact arrangement the Anti-Kickback Statute was written to reach.

Corporate Practice of Medicine Limits on Platform Control

Separate from the kickback exposure, most states bar a business corporation from owning a medical practice or directing a physician's clinical judgment, a restriction known as the corporate practice of medicine doctrine. The standard compliance structure keeps the MSO's ownership limited to non-clinical assets while a physician-owned PC retains prescribing authority. In April 2025, Eli Lilly filed suit in the Northern District of California against telehealth companies including Fella Health and Mochi Health, alleging their management structures controlled and influenced GLP-1 prescribing decisions, including dosage and formulation changes made without an independent medical exam, in violation of state corporate practice of medicine law. The litigation shows that regulators and private plaintiffs are both testing the line between administrative support and clinical control in these arrangements.

Why Early Legal Counsel Is Critical

It is critical that telehealth platforms, prescriber practices, and compounding pharmacies promptly retain healthcare defense counsel before finalizing or defending a GLP-1 telehealth fee arrangement. Early legal intervention can protect the parties' rights, help structure a fee methodology that satisfies the personal services and management contracts safe harbor, avoid inadvertent admissions during an OIG inquiry or state board investigation, preserve relevant defenses, and allow counsel to communicate with investigators on the parties' behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy, the practice, or the platform to unnecessary licensure, financial, and reputational risk.

How Health Law Alliance Can Help

Health Law Alliance represents compounding pharmacies, physician practices, and telehealth platforms structuring or defending GLP-1 prescriber-pharmacy-platform arrangements. We review fee methodologies against the Anti-Kickback Statute's personal services and management contracts safe harbor, assess platform agreements against state corporate practice of medicine restrictions, and represent parties facing OIG inquiries or state board investigations tied to these structures. If your pharmacy, practice, or platform has questions about an existing or proposed GLP-1 telehealth arrangement, contact us for a free, confidential consultation.